Mild Electrical Stimulation with Heat Shock Reduces Visceral Adiposity and Improves Metabolic Abnormalities in Subjects with Metabolic Syndrome or Type 2 Diabetes: Randomized Crossover Trials
Background: The induction of heat shock protein (HSP) 72 by mild electrical stimulation with heat shock (MES + HS), which improves visceral adiposity and insulin resistance in mice, may be beneficial in treating metabolic syndrome (MS) or type 2 diabetes mellitus (T2DM). Methods: Using open-label cr...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2014-11-01
|
| Series: | EBioMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396414000255 |
| _version_ | 1818676136800944128 |
|---|---|
| author | Tatsuya Kondo Kaoru Ono Sayaka Kitano Rina Matsuyama Rieko Goto Mary Ann Suico Shuji Kawasaki Motoyuki Igata Junji Kawashima Hiroyuki Motoshima Takeshi Matsumura Hirofumi Kai Eiichi Araki |
| author_facet | Tatsuya Kondo Kaoru Ono Sayaka Kitano Rina Matsuyama Rieko Goto Mary Ann Suico Shuji Kawasaki Motoyuki Igata Junji Kawashima Hiroyuki Motoshima Takeshi Matsumura Hirofumi Kai Eiichi Araki |
| author_sort | Tatsuya Kondo |
| collection | DOAJ |
| description | Background: The induction of heat shock protein (HSP) 72 by mild electrical stimulation with heat shock (MES + HS), which improves visceral adiposity and insulin resistance in mice, may be beneficial in treating metabolic syndrome (MS) or type 2 diabetes mellitus (T2DM).
Methods: Using open-label crossover trials, 40 subjects with MS or T2DM were randomly assigned using computer-generated random numbers to 12 weeks of therapeutic MES + HS followed by 12 weeks of no treatment, or vice versa. During the intervention period, physical and biochemical markers were measured.
Findings: Compared to no treatment, MES + HS treatment was associated with a significant decrease in visceral adiposity (−7.54 cm2 (−8.61%), 95% CI −8.55 to −6.53 (p = 0.037) in MS, −19.73 cm2 (−10.89%), 95% CI −20.97 to −18.49 (p = 0.003) in T2DM). Fasting plasma glucose levels were decreased by 3.74 mg/dL (−5.28%: 95% CI −4.37 to −3.09 mg/dL, p = 0.029) in MS and by 14.97 mg/dL (10.40%: 95% CI −15.79 to 14.15 mg/dL, p < 0.001) in T2DM, and insulin levels were also reduced by 10.39% and 25.93%, respectively. HbA1c levels showed a trend toward reduction (−0.06%) in MS, and was significantly declined by −0.43% (95% CI −0.55 to −0.31%, p = 0.009) in T2DM. HbA1c level of less than 7.0% was achieved in 52.5% of the MES + HS-treated T2DM patients in contrast to 15% of the non-treated period. Several insulin resistance indices, inflammatory cytokines or adipokines, including C-reactive protein, adiponectin, and tumor necrosis factor-α, were all improved in both groups. In isolated monocytes, HSP72 expression was increased and cytokine expression was reduced following MES + HS treatment. Glucose excursions on meal tolerance test were lower after using MES + HS in T2DM.
Interpretation: This combination therapy has beneficial impacts on body composition, metabolic abnormalities, and inflammation in subjects with MS or T2DM. Activation of the heat shock response by MES + HS may provide a novel approach for the treatment of lifestyle-related diseases.
Funding: Funding for this research was provided by MEXT KAKENHI (Grants-in-Aid for Scientific Research from Ministry of Education, Culture, Sports, Science and Technology, Japan). |
| first_indexed | 2024-12-17T08:38:41Z |
| format | Article |
| id | doaj.art-403bea18954944ce86134408c289eb7f |
| institution | Directory Open Access Journal |
| issn | 2352-3964 |
| language | English |
| last_indexed | 2024-12-17T08:38:41Z |
| publishDate | 2014-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EBioMedicine |
| spelling | doaj.art-403bea18954944ce86134408c289eb7f2022-12-21T21:56:24ZengElsevierEBioMedicine2352-39642014-11-0111808910.1016/j.ebiom.2014.11.001Mild Electrical Stimulation with Heat Shock Reduces Visceral Adiposity and Improves Metabolic Abnormalities in Subjects with Metabolic Syndrome or Type 2 Diabetes: Randomized Crossover TrialsTatsuya Kondo0Kaoru Ono1Sayaka Kitano2Rina Matsuyama3Rieko Goto4Mary Ann Suico5Shuji Kawasaki6Motoyuki Igata7Junji Kawashima8Hiroyuki Motoshima9Takeshi Matsumura10Hirofumi Kai11Eiichi Araki12Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanDepartment of Molecular Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanDepartment of Molecular Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanDepartment of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanBackground: The induction of heat shock protein (HSP) 72 by mild electrical stimulation with heat shock (MES + HS), which improves visceral adiposity and insulin resistance in mice, may be beneficial in treating metabolic syndrome (MS) or type 2 diabetes mellitus (T2DM). Methods: Using open-label crossover trials, 40 subjects with MS or T2DM were randomly assigned using computer-generated random numbers to 12 weeks of therapeutic MES + HS followed by 12 weeks of no treatment, or vice versa. During the intervention period, physical and biochemical markers were measured. Findings: Compared to no treatment, MES + HS treatment was associated with a significant decrease in visceral adiposity (−7.54 cm2 (−8.61%), 95% CI −8.55 to −6.53 (p = 0.037) in MS, −19.73 cm2 (−10.89%), 95% CI −20.97 to −18.49 (p = 0.003) in T2DM). Fasting plasma glucose levels were decreased by 3.74 mg/dL (−5.28%: 95% CI −4.37 to −3.09 mg/dL, p = 0.029) in MS and by 14.97 mg/dL (10.40%: 95% CI −15.79 to 14.15 mg/dL, p < 0.001) in T2DM, and insulin levels were also reduced by 10.39% and 25.93%, respectively. HbA1c levels showed a trend toward reduction (−0.06%) in MS, and was significantly declined by −0.43% (95% CI −0.55 to −0.31%, p = 0.009) in T2DM. HbA1c level of less than 7.0% was achieved in 52.5% of the MES + HS-treated T2DM patients in contrast to 15% of the non-treated period. Several insulin resistance indices, inflammatory cytokines or adipokines, including C-reactive protein, adiponectin, and tumor necrosis factor-α, were all improved in both groups. In isolated monocytes, HSP72 expression was increased and cytokine expression was reduced following MES + HS treatment. Glucose excursions on meal tolerance test were lower after using MES + HS in T2DM. Interpretation: This combination therapy has beneficial impacts on body composition, metabolic abnormalities, and inflammation in subjects with MS or T2DM. Activation of the heat shock response by MES + HS may provide a novel approach for the treatment of lifestyle-related diseases. Funding: Funding for this research was provided by MEXT KAKENHI (Grants-in-Aid for Scientific Research from Ministry of Education, Culture, Sports, Science and Technology, Japan).http://www.sciencedirect.com/science/article/pii/S2352396414000255Metabolic syndromeType 2 diabetesHeat shock responseInsulin resistanceChronic inflammation |
| spellingShingle | Tatsuya Kondo Kaoru Ono Sayaka Kitano Rina Matsuyama Rieko Goto Mary Ann Suico Shuji Kawasaki Motoyuki Igata Junji Kawashima Hiroyuki Motoshima Takeshi Matsumura Hirofumi Kai Eiichi Araki Mild Electrical Stimulation with Heat Shock Reduces Visceral Adiposity and Improves Metabolic Abnormalities in Subjects with Metabolic Syndrome or Type 2 Diabetes: Randomized Crossover Trials EBioMedicine Metabolic syndrome Type 2 diabetes Heat shock response Insulin resistance Chronic inflammation |
| title | Mild Electrical Stimulation with Heat Shock Reduces Visceral Adiposity and Improves Metabolic Abnormalities in Subjects with Metabolic Syndrome or Type 2 Diabetes: Randomized Crossover Trials |
| title_full | Mild Electrical Stimulation with Heat Shock Reduces Visceral Adiposity and Improves Metabolic Abnormalities in Subjects with Metabolic Syndrome or Type 2 Diabetes: Randomized Crossover Trials |
| title_fullStr | Mild Electrical Stimulation with Heat Shock Reduces Visceral Adiposity and Improves Metabolic Abnormalities in Subjects with Metabolic Syndrome or Type 2 Diabetes: Randomized Crossover Trials |
| title_full_unstemmed | Mild Electrical Stimulation with Heat Shock Reduces Visceral Adiposity and Improves Metabolic Abnormalities in Subjects with Metabolic Syndrome or Type 2 Diabetes: Randomized Crossover Trials |
| title_short | Mild Electrical Stimulation with Heat Shock Reduces Visceral Adiposity and Improves Metabolic Abnormalities in Subjects with Metabolic Syndrome or Type 2 Diabetes: Randomized Crossover Trials |
| title_sort | mild electrical stimulation with heat shock reduces visceral adiposity and improves metabolic abnormalities in subjects with metabolic syndrome or type 2 diabetes randomized crossover trials |
| topic | Metabolic syndrome Type 2 diabetes Heat shock response Insulin resistance Chronic inflammation |
| url | http://www.sciencedirect.com/science/article/pii/S2352396414000255 |
| work_keys_str_mv | AT tatsuyakondo mildelectricalstimulationwithheatshockreducesvisceraladiposityandimprovesmetabolicabnormalitiesinsubjectswithmetabolicsyndromeortype2diabetesrandomizedcrossovertrials AT kaoruono mildelectricalstimulationwithheatshockreducesvisceraladiposityandimprovesmetabolicabnormalitiesinsubjectswithmetabolicsyndromeortype2diabetesrandomizedcrossovertrials AT sayakakitano mildelectricalstimulationwithheatshockreducesvisceraladiposityandimprovesmetabolicabnormalitiesinsubjectswithmetabolicsyndromeortype2diabetesrandomizedcrossovertrials AT rinamatsuyama mildelectricalstimulationwithheatshockreducesvisceraladiposityandimprovesmetabolicabnormalitiesinsubjectswithmetabolicsyndromeortype2diabetesrandomizedcrossovertrials AT riekogoto mildelectricalstimulationwithheatshockreducesvisceraladiposityandimprovesmetabolicabnormalitiesinsubjectswithmetabolicsyndromeortype2diabetesrandomizedcrossovertrials AT maryannsuico mildelectricalstimulationwithheatshockreducesvisceraladiposityandimprovesmetabolicabnormalitiesinsubjectswithmetabolicsyndromeortype2diabetesrandomizedcrossovertrials AT shujikawasaki mildelectricalstimulationwithheatshockreducesvisceraladiposityandimprovesmetabolicabnormalitiesinsubjectswithmetabolicsyndromeortype2diabetesrandomizedcrossovertrials AT motoyukiigata mildelectricalstimulationwithheatshockreducesvisceraladiposityandimprovesmetabolicabnormalitiesinsubjectswithmetabolicsyndromeortype2diabetesrandomizedcrossovertrials AT junjikawashima mildelectricalstimulationwithheatshockreducesvisceraladiposityandimprovesmetabolicabnormalitiesinsubjectswithmetabolicsyndromeortype2diabetesrandomizedcrossovertrials AT hiroyukimotoshima mildelectricalstimulationwithheatshockreducesvisceraladiposityandimprovesmetabolicabnormalitiesinsubjectswithmetabolicsyndromeortype2diabetesrandomizedcrossovertrials AT takeshimatsumura mildelectricalstimulationwithheatshockreducesvisceraladiposityandimprovesmetabolicabnormalitiesinsubjectswithmetabolicsyndromeortype2diabetesrandomizedcrossovertrials AT hirofumikai mildelectricalstimulationwithheatshockreducesvisceraladiposityandimprovesmetabolicabnormalitiesinsubjectswithmetabolicsyndromeortype2diabetesrandomizedcrossovertrials AT eiichiaraki mildelectricalstimulationwithheatshockreducesvisceraladiposityandimprovesmetabolicabnormalitiesinsubjectswithmetabolicsyndromeortype2diabetesrandomizedcrossovertrials |